Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 23 | -0.25 Increased by +21.88% | -0.29 Increased by +47.56% |
| Mar 16, 23 | -0.28 Decreased by -7.69% | -0.35 Increased by +57.14% |
| Mar 15, 23 | -0.28 Decreased by -7.69% | -0.35 Increased by +57.14% |
| Nov 14, 22 | -0.32 Decreased by -45.45% | -0.28 Decreased by -51.02% |
| Nov 10, 22 | -0.32 Decreased by -45.45% | -0.28 Decreased by -51.02% |
| May 11, 22 | -0.26 | -0.33 Increased by +64.28% |
| May 10, 22 | -0.26 | -0.33 Increased by +64.28% |
| Mar 17, 22 | -0.22 | -0.40 Increased by +112.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -2.90 M Decreased by -8.72% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | 2.03 M Increased by +115.59% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -3.54 M Increased by +23.71% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -2.62 M Increased by +33.45% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -2.67 M Decreased by -81.11% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -13.03 M Decreased by -1.09 K% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -4.64 M Decreased by -253.14% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -3.94 M Decreased by -331.11% | Decreased by N/A% Decreased by N/A% |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.